Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.

Article  CAS  PubMed  Google Scholar 

Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077–84.

Article  CAS  PubMed  Google Scholar 

Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–49.

Article  CAS  PubMed  Google Scholar 

Desjonquières A, Chevallier P, Thomas X, et al. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J. 2016;6:e504.

Article  Google Scholar 

Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023;141:3019–30.

Google Scholar 

Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75–87.

Article  CAS  PubMed  Google Scholar 

Thomas X. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development. Exp Opin Invest Drugs. 2023;32:37–52.

Article  CAS  Google Scholar 

Lambe CU, Averett DR, Paff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55:3352–6.

CAS  PubMed  Google Scholar 

Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006;12:5329–35.

Article  CAS  PubMed  Google Scholar 

Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory malignancies. J Clin Oncol. 2005;23:3396–403.

Article  CAS  PubMed  Google Scholar 

Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol. 2005;23:3376–82.

Article  CAS  PubMed  Google Scholar 

DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504–11.

Article  PubMed  Google Scholar 

Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:2753–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015;62:1176–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain P, Kantarjian H, Ravandi F, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014;28:973–5.

Article  CAS  PubMed  Google Scholar 

Rowntree CJ, Kirkwood AA, Clifton-Hadley L, et al. First analysis of the UKALL 14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK/09/006). In: Annual Meeting of the American Society of Hematology 2021; abstract 366.

Kadia T, Gandhi V, Thomas DA, et al. Phase I study of continuous-infusion nelarabine in patients with advanced lymphoid malignancies. Blood. 2011;118:4239.

Article  Google Scholar 

Pikman Y, Alexe G, Roti G, et al. Synergistic drug combinations with CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2017;23:1012–24.

Article  CAS  PubMed  Google Scholar 

Sawai CM, Freund J, Oh P, et al. Therapeutic targeting of the cyclin D3: CDK4/6 complex in T cell leukemia. Cancer Cell. 2012;22:452–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) in acute leukemias. Cancer Chemother Pharmacol. 2013;72:897–908.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olson CM, Jiang B, Erb MA, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018;14:163–70.

Article  CAS  PubMed  Google Scholar 

Cidado J, Boiko S, Proia T, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922–34.

Article  CAS  PubMed  Google Scholar 

Simonin M, Schmidt A, Bontoux C, et al. Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL. Blood. 2023;141:1353–8.

Article  CAS  PubMed  Google Scholar 

Bykov VJN, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89–102.

Article  CAS  PubMed  Google Scholar 

Kim R, Boissel N, Touzart A, et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem cell transplantation. Leukemia. 2020;34:1730–40.

Article  CAS  PubMed  Google Scholar 

De Smedt R, Morscio J, Reunes L, et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood. 2020;135:1685–95.

Article  PubMed  Google Scholar 

Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125:1759–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verbeke D, Gielen O, Jacobs K, et al. Ruxolitinib synergizes with dexamethasone for the treatment of T-cell acute lymphoblastic leukemia. Hemasphere. 2019;3: e310.

Article  PubMed  PubMed Central  Google Scholar 

Bodaar K, Yamagata N, Barthe A, et al. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2022;36:1499–507.

Article  CAS  PubMed  PubMed Central  Google Scholar